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Introduction
Activated leukocyte cell adhesion molecule (ALCAM, CD166)
is a novel member of the immunoglobulin superfamily of
adhesion molecules. Unlike its name suggests, ALCAM is not
only expressed by activated leukocytes (Bowen et al., 1995)
and monocytes (Levesque et al., 1998), but also by
hematopoietic progenitor cells (Uchida et al., 1997; Nelissen
et al., 2000a), bone marrow stromal cells (Cortes et al., 1999)
and hematopoiesis-supporting osteoblastic cells (Nelissen et
al., 2000a). In addition to expression by hematopoietic cells
and hematopoiesis-related tissues, ALCAM is expressed by
metastasizing melanoma (Degen et al., 1998) and by prostate
adenocarcinoma (Kristiansen et al., 2003). Neuronal cells
express substantial levels of ALCAM (Tanaka et al., 1991) and
multiple other tissues stain positive for ALCAM (Bowen et al.,
1995; Degen et al., 1998; Nelissen et al., 1999).
ALCAM consists of five extracellular Ig-like domains and
is a highly glycosylated type I transmembrane molecule with
a short (32 AA) cytoplasmic tail and an observed molecular
weight of 105 kDa (Bowen et al., 1995). Besides binding to
CD6 (Bowen et al., 1995; Bowen et al., 1996), ALCAM
mediates homotypic ALCAM-ALCAM interactions (Uchida
et al., 1997; Nelissen et al., 2000b). Although the precise
function of ALCAM is largely unknown, ALCAM-mediated
interactions are important during neural development (Tanaka
et al., 1991; Stephan et al., 1999), maturation of hematopoietic
stem cells in blood forming tissues (Uchida et al., 1997; Cortes
et al., 1999; Ohneda et al., 2001), immune responses (Bowen
et al., 1995) and tumor progression (Degen et al., 1998). In
view of the diversity of cellular processes in which ALCAM
is implicated, tight regulation of ALCAM-mediated adhesion
is required to prevent aberrant adhesive homotypic or
heterotypic interactions. However, the signaling pathways that
lead to modulation of ALCAM-mediated adhesion remain
elusive. Identification of the molecular mechanism underlying
ALCAM-mediated adhesion will further contribute to our
understanding of the function of ALCAM in diverse tissues.
We have shown that homotypic ALCAM-mediated
interactions are dynamically regulated through the actin
cytoskeleton (Nelissen et al., 2000b). We demonstrated that
stable, homotypic ALCAM-mediated adhesion requires a
transient release of ALCAM from the actin cytoskeleton, as
induced by partial disruption of the cytoskeleton with
cytochalasin D (CytD). Upon CytD treatment of the cells, we
observed a significant increase in lateral mobility of ALCAM
molecules. This release from the actin cytoskeleton and
enhanced mobility results in the formation of high avidity
clusters of ALCAM molecules on the cell surface, which are
required for strong adhesive ALCAM-ALCAM interactions.
K562 cells expressing a GPI-anchored ALCAM mutant failed
to adhere to immobilized ALCAM-Fc in response to CytD
treatment, demonstrating the importance of the cytoplasmic
domain of ALCAM for regulation by the actin cytoskeleton.
In the present study, we extend these findings by examining
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The activated leukocyte cell adhesion molecule (ALCAM)
is dynamically regulated by the actin cytoskeleton. In this
study we explored the molecular mechanisms and signaling
pathways underlying the cytoskeletal restraints of this
homotypic adhesion molecule. We observed that ALCAM-
mediated adhesion induced by cytoskeleton-disrupting
agents is accompanied by activation of the small GTPases
RhoA, Rac1 and Cdc42. Interestingly, unlike adhesion
mediated by integrins or cadherins, ALCAM-mediated
adhesion appears to be independent of Rho-like GTPase
activity. By contrast, we demonstrated that protein
kinase C (PKC) plays a major role in ALCAM-mediated
adhesion. PKC inhibition by chelerythrine chloride and
myristoylated PKC pseudosubstrate, as well as PKC
downregulation by PMA strongly reduce cytoskeleton-
dependent ALCAM-mediated adhesion. Since serine and
threonine residues are dispensable for ALCAM-mediated
adhesion and ALCAM is not phosphorylated, we can rule
out that ALCAM itself is a direct PKC substrate. We
conclude that PKCa plays a dominant role in cytoskeleton-
dependent avidity modulation of ALCAM.
Key words: ALCAM, CD166, PKC, Cytoskeleton, Avidity, Rho-like
GTPases
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two signaling pathways potentially involved in ALCAM-
mediated adhesion. The first pathway of interest involves the
small GTPases RhoA, Rac1 and Cdc42, which are key players
in the organization of the actin cytoskeleton (Hall, 1998;
Schoenwaelder and Burridge, 1999). RhoA promotes the
formation and maintenance of stress fibers and focal adhesions,
whereas Rac and Cdc42 regulate the formation of actin-rich
protrusions such as lamellipodia and filopodia. RhoA, Rac1
and Cdc42 are highly involved in the regulation of adhesion
mediated by integrins (Mackay and Hall, 1998; D’Souza-
Schorey et al., 1998; Gimond et al., 1999) and cadherins
(Braga, 2002; Yap and Kovacs, 2003). The Rho-like GTPases
are also implicated in the clustering and adhesion of a number
of Ig-CAMs: RhoA regulates the assembly of stable adhesions
between endothelial cells and monocytes via clustering of
the receptors ICAM-1, VCAM-1 and E-selectin, and their
association with the actin cytoskeleton (Wojciak-Stothard et
al., 1999). Also, clustering of VCAM-1 and possibly other Ig-
CAMs initiates a signaling pathway that involves Rac1 (Van
Wetering et al., 2003). Here, in sharp contrast to integrins and
cadherins, we find no evidence for involvement of these
GTPases in adhesion mediated by ALCAM.
Protein kinase C isoforms are another group of signaling
molecules that may be relevant with respect to ALCAM-
mediated adhesion. They were shown to significantly
contribute to cytoskeletal rearrangements (Masson-Gadais
et al., 1997; Keenan and Kelleher, 1998) and even bind
filamentous actin (Slater et al., 2000). In locomotory T cells,
PKCb is involved in LFA-1-mediated signaling and
cytoskeletal scaffolding (Altman and Villalba, 2002). PKC q
appears to be associated with the actin cytoskeleton in T cells
and is essential for T-cell activation (reviewed in Volkov et al.,
2001). Moreover, PMA stimulation of lymphocytes induces
b 2-integrin-mediated adhesion in a manner similar to CytD
(Kucik et al., 1996). These findings underscore the possible
involvement of PKC in cytoskeleton-dependent, homotypic
ALCAM-mediated adhesion. Here we demonstrate that PKC a
plays an essential role in cytoskeleton-dependent avidity
modulation of ALCAM.
Materials and Methods
Chemicals and antibodies
All chemicals were purchased from Sigma (St Louis, MO) unless
stated otherwise. Stock solutions of cytochalasin D (CytD),
latrunculin A (LatA, Molecular Probes, Leiden, The Netherlands),
phorbol-12-myristate-13-acetate (PMA) and chelerythrine chloride
were prepared in dimethylsulfoxide (DMSO) and stored at –20°C.
Stock solutions of myristoylated cell-permeable PKC inhibitor 19-27
(Calbiochem, La Jolla, CA) were prepared in Tris-buffer and stored
at –20°C. [32P]-Disodiumphosphate and [35S]methionine/cysteine
were from MP Biomedicals Inc. (Irvine, CA).
Anti-ALCAM monoclonal antibodies: J4-81 (IgG1 isotype) and
FITC-conjugated J4-81 were purchased from Antigenix America
(Huntington Station, NY). AZN-L50 (IgG2A isotype) and AZN-L51
(IgG1 isotype) were generated in our laboratory by immunizing
BALB/C mice with K562-ALCAM. Goat-anti-human Fc-(Fab ¢ )2
fragments were purchased from Jackson ImmunoResearch
(Westgrove, PA), FITC-conjugated goat-anti-mouse (Fab¢ )2 fragments
were from Zymed Laboratories (San Francisco, CA) and FITC-
conjugated goat-anti-human Fc-(Fab¢ )2 fragments were from Cappel
Inc. (West Chester, PA). Alexa 488-conjugated goat-anti-mouse IgG
(H+L) and Texas Red-X Phalloidin were obtained from Molecular
Probes (Eugene, OR). Anti-PKC isotype-specific antibodies and
corresponding blocking peptides are from Gibco (Paisley, Scotland).
Recombinant ALCAM-Fc was produced and purified as described
elsewhere (Nelissen et al., 2000b), and recombinant CD6-Fc was
purchased from R&D Systems (Minneapolis, MN).
Cells, expression constructs, transfections and retroviral
transductions
All culture media, serum and antibiotics were purchased from Life
Technologies (Breda, The Netherlands). All culture media were
supplemented with 1% antibiotics/antimycotics. Myelomonocytic
KG1 cells were cultured in Iscove’s Modified Dulbecco’s Medium
containing 10% FCS. Erythroleukemic K562 cells were cultured in
RPMI 1640 containing 10% FCS. K562-ALCAM were generated and
maintained as described elsewhere (Nelissen et al., 2000b). To induce
downregulation of PKC, cells were cultured for 16 hours in the
presence of 50 nM PMA.
For mutagenesis, the full length cDNA of ALCAM was cloned in
pALTER (Promega) and according to the manufacturer’s protocol,
serine-to-alanine and threonine-to-alanine mutations were introduced.
For mutation of the serines in the cytoplasmic tail (at positions 554
and 558), the oligonucleotide 5 ¢ -CATGAAGAAGGGCAAAGACTG-
CAGCAAAACATGTA-3¢ was used and for mutation of the
threonines at positions 556 and 581, the oligonucleotides 5 ¢ -GA-
AGTCAAAGGCTGCATCAAAAC-3 ¢ and 5¢ -CAATCACAAAGCT-
GAAGCCTAAC-3¢ were used, respectively. Sequence analysis was
performed to confirm the mutations and the cDNA was recloned in
pRc/CMV (Invitrogen). These constructs were used for transfection
of K562 cells by electroporation with a Gene Pulser (BioRad,
Hercules, CA) at 960 m F and 230 V resulting in K562-ALCAM D Ser
and K562-ALCAM D Thr, respectively. The mutant transfectants were
cultured like K562-ALCAM. Myc-tagged V14-RhoA, N19-RhoA,
V12-Rac1, N17-Rac1, V12-Cdc42, N17-Cdc42, and L61-Rac1 and
HA-tagged C1199-Tiam1, cloned into the retroviral vector LZRS-
IRES-Neo, were introduced into KG1 cells and K562-ALCAM cells
by retroviral transduction and selected on G418 (125 m g/ml). The
expression levels of Rho-like GTPases and C1199-Tiam1 were
analyzed by conventional western blotting procedures using the
antibodies 9E10 (anti-Myc) and 3F10 (anti-HA).
Flow cytometry
Cells were washed with PBA [PBS containing 1% (w/v) BSA and
0.05% (w/v) NaN3] and stained for 30 minutes at 4°C with primary
antibody (2-5 m g/ml in PBA). Cells were washed with PBA and
incubated with FITC-conjugated goat-anti-mouse (Fab¢ )2 secondary
antibody. After washing, cells were analyzed on a FACScan analyzer
(Becton Dickinson, Oxnard, CA). The gates were set to exclude dead
cells and 5000 gated cells were analyzed. Data are displayed as
histograms of fluorescence intensity versus cell count.
Plate adhesion assay
Plate adhesion assays were performed as described earlier (Nelissen et
al., 2000b). Briefly, flatbottom 96-well plates (Maxisorp, NUNC,
Roskilde, Denmark) were pre-coated with 4 m g/ml goat-anti-human-Fc-
(Fab¢ )2 in TSM (20 mM Tris, 150 mM NaCl, 1 mM CaCl2, 1 mM
MgCl2, pH 8.0). The plates were blocked with 1% (w/v) BSA and
subsequently coated with 250 ng/ml ALCAM-Fc or CD6-Fc. Cells
(2· 104 per well) were labeled with Calcein-AM (Molecular Probes,
Eugene, OR) and where applicable, cells were pre-treated with CytD
(2.5 m g/ml) or LatA (5 m g/ml) for 30 minutes at 37°C in culture
medium. Chelerythrine chloride (5 m M) and cell-permeable
myristoylated PKC inhibitor (100 m M) or equivalent amounts of solvent
were pre-incubated for 10 minutes at 37°C. Antibody AZN-L50 (10
m g/ml) was pre-incubated for 5-10 minutes at room temperature (RT).
Journal of Cell Science 117 (13)
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Cells were allowed to adhere in triplicate wells to the coated plates for
45 minutes in culture medium at 37°C in the presence or absence of the
blocking mAb. Non-adherent cells were removed by repeated washing
with TSM/0.5% (w/v) BSA at 37°C. Cells were lysed with lysis buffer
[50 mM Tris, 0.1% (w/v) SDS] and fluorescence was quantified in a
cytofluorometer (Perseptive Biosystems). Adhesion was expressed as
the mean percentage (±s.d.) of bound cells from triplicate wells.
ALCAM-specific adhesion is calculated by subtracting adhesion in the
presence of both blocking antibody and stimulus from adhesion in the
presence of the stimulus alone.
Fluorescent bead adhesion assay
Carboxylate-modified TransFluorSpheres (488/645 nm, 1.0 m M;
Molecular Probes, Eugene, OR) were coated with ALCAM-Fc as
described previously for ICAM3-Fc (Geijtenbeek et al., 1999), and
the adhesion assay was performed as described (Geijtenbeek et al.,
1999). In brief, cells were resuspended in adhesion buffer [20 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2 and
0.5% BSA) at a final concentration of 5 · 106 cells/ml. Fifty-thousand
cells were pre-incubated with mAb AZN-L50 (10 m g/ml) for 10
minutes at RT. Ligand-coated fluorescent beads (20 beads/cell) were
added, and the suspension was incubated for 30 minutes at 37°C.
Adhesion was determined by measuring the percentage of cells that
have bound fluorescent beads using flow cytometry.
Soluble ligand-binding assay
ALCAM-expressing cells (5· 104 per well) were resuspended in 50 m l
of the indicated dilutions of ALCAM-Fc in medium and allowed to
bind ligand for 30 minutes at 37°C. Where indicated, cells were pre-
incubated with chelerythrine chloride (5 m M) or cell-permeable
myristoylated PKC inhibitor (100 m M) for 10 minutes at 37°C, or for
30 minutes at 37°C with CytD (2.5 m g/ml) prior to addition of
ALCAM-Fc. Cells were washed with pre-warmed medium and
subsequently incubated with FITC-conjugated goat-anti-human-Fc
antibodies for 15 minutes at 37°C. After washing, the cells were
analyzed by flow cytometry and the percentage of cells that have
bound ligand was quantified.
GTPase activity assays
GTPase activity assays were performed as described elsewhere
(Sander et al., 1999). Briefly, GST-PAK-CD and GST-C21 fusion
proteins, containing the Rac1- and Cdc42-binding region from
PAK1B and the RhoA-binding domain from Rhotekin, respectively,
were produced in Escherichia coli BL21 cells. The fusion proteins
were purified and bound to glutathione-Sepharose 4B beads
(Amersham-Pharmacia) as described (Sander et al., 1999). Serum-
starved KG1, K562, K562-ALCAM cells were treated with or without
CytD (2.5 m g/ml) for 30 minutes at 37°C in suspension and cells were
lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 2 mM MgCl2, 1% NP-
40, 10% glycerol, 100 mM NaCl, 1 mM PMSF, 1 m g/ml leupeptin and
aprotinin). Alternatively, serum-starved K562-ALCAM cells were
treated with or without CytD, and subsequently allowed to adhere for
45 minutes to an ALCAM-Fc- (250 ng/ml) or BSA- (0.5 mg/ml)
coated cell culture dish, in the presence or absence of the blocking
antibody AZN-L50, before lysing the cells. The cell lysates were
incubated with GST-PAK-CD or GST-C21 fusion proteins bound to
glutathione-Sepharose beads. The beads and the proteins bound to the
beads were washed three times in excess lysis buffer, eluted in
Laemmli sample buffer, and analyzed for bound Cdc42, Rac1 or
RhoA by western blotting. Aliquots of total lysates served as a control
for total amounts of proteins. GTPases were detected using antibodies
against Cdc42 (rabbit polyclonal antibody from Santa Cruz
Biotechnology), Rac1 (mAb from Upstate Biotechnology) or RhoA
(mAb from Santa Cruz Biotechnology).
Detection of PKC isotypes by western blotting
Cells were cultured in the presence or absence of PMA (50 nM) and
washed once in PBS. Cell lysates were subjected to SDS-PAGE.
Proteins were transferred to polyvinylidine difluoride membranes
(Immobilon P, Millipore) by western blotting. Membranes were
blocked for 1 hour with PBS containing 0.2% (w/v) I-Block reagent
and 0.1% (v/v) Tween-20 and incubated overnight with PKC-isotype-
specific antibodies diluted 1:500 in PBS containing 0.1% (w/v) I-
Block reagent and 0.2% (v/v) Tween-20. To demonstrate the
specificity of the reaction, control membranes were incubated with
PKC-isotype-specific antibodies in the presence of the corresponding
PKC-isotype-specific blocking peptide diluted 1:1000. Membranes
were washed with PBS containing 0.3% (v/v) Tween-20 and
incubated for 1 hour with goat-anti-rabbit IgG antibodies conjugated
to alkaline phosphatase diluted 1:1000 in PBS containing 0.1% (w/v)
I-Block reagent and 0.2% (v/v) Tween-20. Membranes were washed
as before and stained with 0.1 M diethanolamine, 0.34 mg/ml
Nitroblue tetrazolium, 0.18 mg/ml 5-bromo-4-chloro-3-
indolylphosphate and 50 mM MgCl2.
Confocal laser scan microscopy
Cells were mounted on poly-L-lysine coated glass slides and, where
indicated, treated with CytD (2.5 m g/ml) and/or chelerythrine chloride
(5 m M) for 30 minutes and 10 minutes, respectively. Cells were fixed
with 3.7% formaldehyde, stained for 30 minutes at RT with mAb
AZN-L50 and subsequently incubated with Alexa 488-conjugated
goat-anti-mouse IgG and Texas Red-X phalloidin for 30 minutes at
RT. ALCAM and actin distribution were analyzed by CLSM at 488
nm with a krypton/argon laser on a MRC1024 confocal microscope
(BioRad). The instrument settings were: lens 60 · , magnification 2.5 · ,
iris 2.3 nm, gain 1355 (red) or 1440 (green), laser 26% (red) or 34%
(green).
Radioactive cell labeling and immunoprecipitation
Cells were cultured for 16 hours in the presence or absence of PMA
(50 nM) and were pre-incubated for 1 hour in serum- and phosphate-
free RPMI 1640 medium prior to labeling with [32P]-
disodiumphosphate, 400 m Ci per 5 · 106 cells for 3 hours at 37°C.
Subsequently, cells were treated with or without 50 nM PMA for 15
minutes at 37°C. Alternatively, cells were labeled for 16 hours with a
mixture of [35S]methionine/cysteine (500 m Ci per 10 · 106 cells) in
serum- and methionine/cysteine-free RPMI 1640 medium. Cell
lysates were subjected to immunoprecipitation with 1 m g of AZN-L51
antibody coupled to Protein G Sepharose 4 Fast Flow beads
(Amersham Biosciences). Bound proteins were eluted by boiling in
Laemli sample buffer and were analyzed on a 10% SDS-PAGE gel
under reducing conditions.
Results
Induction of cytoskeleton-dependent ALCAM-mediated
adhesion is not caused by enhanced ligand-binding
affinity
KG1 myelomonocytic cells and ALCAM-transfected K562
cells (K562-ALCAM) both express similar levels of ALCAM
at the cell surface (Fig. 1A). We have shown that ALCAM-
mediated adhesion of K562-ALCAM cells is dynamically
regulated through the actin cytoskeleton by treating the cells
with agents that specifically disrupt the cortical actin
cytoskeleton (Nelissen et al., 2000b). Likewise, treatment of
KG1 cells with either CytD or LatA strongly induces ALCAM-
specific adhesion to immobilized ALCAM-Fc (Fig. 1B).
Kinetics and ALCAM specificity of KG1 ALCAM-mediated
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adhesion are similar to what has been published for K562-
ALCAM (Nelissen et al., 2000b) (Fig. 1B).
To investigate whether CytD-induced adhesion is regulated
only by the release from cytoskeletal constraints (avidity
regulation) or also affects the relative affinity of ALCAM-
expressing K562 and KG1 cells, we compared binding to
immobilized ALCAM with that of soluble ALCAM-Fc fusion
proteins. CytD treatment does not increase the affinity of
ALCAM-expressing cells for ALCAM-Fc (Fig. 1C). Similar
results were obtained with LatA (data not shown). These
findings demonstrate that release of ALCAM from the actin
cytoskeleton leads to an increase in avidity (i.e. molecule
clustering) rather than in affinity.
CytD, but not ALCAM-mediated adhesion, causes
activation of RhoA, Rac1 and Cdc42
Disruption of the actin cytoskeleton by CytD treatment results
in increased lateral mobility and cluster formation of integrins
(Elemer and Edgington, 1994; Lub et al., 1995), cadherins
(Baumgartner et al., 2003), and other cell adhesion molecules,
such as Ep-CAM (Balzar et al., 1998), leading to increased
adhesion. In addition to disrupting the actin cytoskeleton, Ren
and co-workers (Ren et al., 1999) showed that in quiescent
Swiss 3T3 fibroblasts CytD treatment activates RhoA. This,
together with our previous observations that ALCAM-mediated
adhesion is sensitive to cytoskeletal restraints (Nelissen et al.,
2000b), raises the possibility that effects of CytD or LatA on
ALCAM-mediated adhesion could at least in part be due to
the activation of Rho-like GTPases. We analyzed the effect of
CytD or LatA treatment on the activation of the small GTPases
RhoA, Rac1 and Cdc42 in K562-ALCAM and KG1 cells in
suspension. Upon treatment of serum-starved K562-ALCAM
cells in suspension with 2.5 m g/ml CytD [the optimal
concentration for inducing ALCAM-mediated adhesion
(Nelissen et al., 2000b)], we observed a time-dependent and
transient activation of RhoA. Interestingly, not only RhoA, but
also Cdc42 and to a lesser extent Rac1 are activated upon CytD
treatment (Fig. 2A). Similar observations were made with
parental K562 cells, and when LatA instead of CytD was used
(data not shown). In KG1 cells, a comparable time-dependent
activation of RhoA and Rac1 was observed (Fig. 2B), though
there are differences in kinetics. In K562-ALCAM cells, RhoA
activation is maximal after 30-60 minutes, while Rac GTP
levels are high already in untreated cells and are only slightly
upregulated by CytD. In contrast, KG1 cells show highest RhoA
activity already after 5-15 minutes of CytD treatment while
maximum Rac1 activity is reached after 30-60 minutes.
Conversely, the activation state of the RhoA, Rac1 and
Cdc42 was not altered by adhesion of cells to immobilized
ALCAM or by cross-linking of ALCAM at the cell surface
(data not shown), demonstrating that ALCAM-mediated
adhesion itself does not induce activation of the Rho-like
GTPases.
Dominant negative or constitutively active Rho-like
GTPase mutants do not affect cytoskeleton-dependent
ALCAM-mediated adhesion
To further investigate involvement of Rho-like GTPases in the
Journal of Cell Science 117 (13)
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Fig. 1. (A) Flow-cytometric analysis of ALCAM expression by KG1
and K562-ALCAM cells. The shaded histograms represent the
isotype control, whereas the white histograms represent ALCAM
staining with AZN-L50. (B) ALCAM-mediated adhesion of both
K562-ALCAM (white bars) and KG1 cells (black bars) to
immobilized ALCAM-Fc requires disruption of the actin
cytoskeleton. The cells were pre-incubated for 30 minutes at 37°C
with or without CytD (2.5 m g/ml) or LatA (5 m g/ml) and
subsequently allowed to adhere to an ALCAM-Fc coated plate
(250 ng/ml ALCAM-Fc) for 45 minutes at 37°C in the presence or
absence of the ALCAM-blocking mAb AZN-L50. Non-ALCAM
antibodies did not affect binding, showing that the observed adhesion
is ALCAM-mediated (data not shown). Specific adhesion is
expressed as the mean percentage (±s.d.) of adherent cells from
triplicate wells after subtraction of the adhesion in the presence of
the blocking mAb AZN-L50. Data are representative of three
experiments. (C) CytD treatment does not alter the affinity of K562-
ALCAM (circles) and KG1 cells (triangles) for ALCAM-Fc. Cells
were treated with (open symbols) or without (closed symbols) CytD
(as in B) and subsequently incubated with the indicated dilutions of
ALCAM-Fc. The percentage of cells that have bound ALCAM-Fc is
detected by flow cytometry using a FITC-conjugated secondary goat-
anti-human-Fc antibody.
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induction of ALCAM-mediated adhesion, KG1 cells were
retrovirally transduced with dominant negative (N19-RhoA,
N17-Rac1 and N17-Cdc42) or constitutively active (V14-
RhoA, V12-Rac1, L61-Rac1 and V12-Cdc42) GTPase
mutants. A constitutively active variant of Tiam-1 (C1199-
Tiam-1), an activator of the small GTPase Rac1 (Michiels et
al., 1995), was used as an additional control to investigate
the involvement of Rac1 in ALCAM-mediated adhesion.
Expression of all GTPase variants and C1199-Tiam-1 was
confirmed by western blotting (Fig. 3A). ALCAM surface
expression, determined by flow cytometry, was not affected by
stable expression of either of the Rho-like GTPase mutants or
C1199-Tiam1 (data not shown).
Spontaneous adhesion to ALCAM-Fc coated beads was
neither significantly altered upon expression of any of the Rho-
like GTPase mutants or C1199-Tiam1 in KG1 cells (Fig. 3B),
nor did we observe induction of spontaneous adhesion or
alteration of CytD-induced adhesion to immobilized ALCAM-
Fc (data not shown). Furthermore, treatment of KG1 and K562
ALCAM cells with the Rho-kinase inhibitor Y-27632 did not
affect adhesion to both soluble and immobilized ALCAM (data
not shown). Together, these data strongly indicate that Rho
GTPase-activity does not affect ALCAM-mediated adhesion.
Cytoskeleton-dependent, homotypic ALCAM-mediated
adhesion requires active PKC
PKC isoforms play a pivotal role in immune cell signaling and
the regulation of cell adhesion, and have been implicated in
cytoskeletal rearrangements (Masson-Gadais et al., 1997;
Keenan and Kelleher, 1998; Volkov et al., 2001). Therefore, we
investigated the role of PKC in the molecular mechanisms
underlying cytoskeleton-dependent, homotypic ALCAM-
mediated adhesion. KG1 and K562-ALCAM cells were pre-
treated with CytD in combination with increasing amounts of
either the PKC inhibitor chelerythrine chloride or with an
inhibitory myristoylated PKC pseudosubstrate, specific for
PKCa and PKCb (Fig. 4A). A significant, concentration-
dependent reduction of CytD-induced ALCAM-mediated
adhesion was observed for both ALCAM-expressing cell lines.
To investigate whether the necessity for PKC is restricted to
CytD or whether this applies to induction of ALCAM-
mediated adhesion upon disruption of the actin cytoskeleton in
general, the effect of chelerythrine chloride (5 m M) and
myristoylated PKC pseudosubstrate (100 m M) on LatA-
induced ALCAM-mediated adhesion was assessed. Inhibition
of PKC not only reduced CytD-induced ALCAM-mediated
adhesion, but also significantly inhibited LatA-induced
Fig. 2. CytD and LatA transiently activate RhoA, Rac1 and Cdc42.
K562-ALCAM cells (A) and KG1 cells (B) in suspension were
treated with 2.5 m g/ml CytD for the indicated time. Subsequently,
cell lysates were incubated with GST-PAK-CD or GST-C21 and the
bound RhoA, Rac1 and Cdc42 molecules were detected by western
blot with the respective antibodies. Total lysates served as a control
for analyzing total amounts of RhoA, Rac1 or Cdc42 on western blot
using the respective antibodies. Similar observations were made
using parental K562 cells (data not shown).
Fig. 3. (A) Expression of Myc-tagged Rho-like GTPase-mutants and
HA-tagged C1199-Tiam1 in KG1. KG1 cells were retrovirally
transduced with dominant negative (N19-RhoA, N17-Rac1, N17-
Cdc42) or constitutively active (V14-RhoA, V12-Rac1, V12-Cdc42,
L61-Rac1) GTPase mutants, or with C1199-Tiam1. Cells were lysed
and expression of the mutants was detected by western blotting using
anti-Myc and anti-HA antibodies, respectively. C1199-Tiam1 and the
Rho-like GTPase mutants migrated according to the expected heights
(RhoA > Rac1=Cdc42). (B) Rho-like GTPase mutants and C1199-
Tiam1 do not alter adhesion of KG1 cells. Cells expressing either
dominant negative GTPase (N19-RhoA, N17-Rac1, N17-Cdc42),
constitutively active GTPase (V14-RhoA, V12-Rac1, V12-Cdc42,
L61-Rac1) or C1199-Tiam1 were allowed to adhere to ALCAM-Fc-
coated beads after pre-incubation with (white bars) or without (black
bars) mAb AZN-L50, for 45 minutes at 37°C. Adhesion is expressed
as the percentage of bound cells. Data are representative of three
independent experiments.
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adhesion (Fig. 4B), suggesting a contribution of PKC to
clustering and subsequent stable adhesion. The effect of PKC
inhibition on ALCAM-mediated adhesion was not due to a
direct effect of CytD or LatA on PKC, since PKC activity, as
determined by Bosch et al. (Bosch et al., 1998), was not altered
in the presence of CytD or LatA (data not shown). Activation
of PKC by the addition of PMA (50 nM) did not induce
adhesion (data not shown), indicating that PKC alone is not
sufficient to overcome the cytoskeletal restraints, but that
disruption of the actin cytoskeleton has to coincide with PKC
action.
To investigate whether the inhibition of PKC affects the
cell surface distribution of ALCAM, CLSM analysis was
performed. In non-treated KG1 cells, ALCAM is randomly
distributed at the plasma membrane and co-localizes with
cortical actin (Fig. 4Ca). Upon treatment with CytD we
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Fig. 4. (A) Inhibition of PKC dose-dependently reduced CytD-induced adhesion. KG1 cells were
pre-treated for 10 minutes at 37°C with increasing concentrations of either chelerythrine chloride
(black bars) or myristoylated PKC inhibitor (white bars) in combination with CytD (2.5 m g/ml).
Both inhibitors of PKC significantly reduce CytD-induced adhesion to immobilized ALCAM.
(B) PKC requirement is not restricted to CytD but applies to LatA as well. KG1 cells were pre-
treated with chelerythrine chloride (Chel, 5 m M) or myristoylated PKC inhibitor (Myr, 100 m M)
for 10 minutes at 37°C in combination with either CytD (2.5 m g/ml, black bars) or LatA (5 m g/ml,
gray bars). Induction of adhesion by both cytoskeleton-disrupting drugs is equally inhibited by
both chelerythrine chloride and myristoylated PKC inhibitor, demonstrating that the requirement
for PKC is not restricted to the mode of action of CytD in itself. Similar observations were made
for K562-ALCAM (not shown). (C) Analysis of the distribution of ALCAM and actin by CLSM.
KG1 cells were pre-treated without (a) or with CytD (2.5 m g/ml, b), or with a combination of
CytD and chelerythine chloride (Chel, 5 m M, c). Cells were stained with mAb AZN-L50 (green)
and Texas Red-X phalloidin (red). For each preparation the same instrument settings were used. The scale bar represents 10 m m. Similar results
were obtained with K562-ALCAM cells (not shown). (D) PKC requirement is not restricted to homotypic ALCAM-mediated adhesion induced
by cytoskeleton-disrupting agents, but also applies to heterotypic ALCAM-CD6 adhesion. KG1 cells were pre-treated with PKC inhibitors as
described in B, in the presence or absence of CytD (2.5 m g/ml). Cells were allowed to adhere to a plate coated with 250 ng/ml of CD6-Fc
(white bars) or ALCAM-Fc (black bars) for 45 minutes at 37°C. Both spontaneous and CytD-induced ALCAM-CD6 adhesion are inhibited by
chelerithrine chloride and myristoylated PKC inhibitor. Similar observations were made for K562-ALCAM cells (not shown).
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observed a marked clustering of ALCAM at the cell surface,
and these clusters partially co-localize with the local actin
accumulations induced by CytD (Fig. 4Cb). Addition of the
PKC inhibitor chelerythrine chloride did not affect the CytD-
induced ALCAM clusters (Fig. 4Cc). Similar findings were
obtained with myristoylated PKC inhibitor. Furthermore,
neither chelerythrine chloride nor myristoylated PKC inhibitor
had an effect on cells that were not incubated with CytD (data
not shown). These results indicate that inhibition of PKC does
not lead to changes in the cell surface distribution of ALCAM,
suggesting that the involvement of PKC in ALCAM-mediated
adhesion does not take place at the level of cluster formation.
PKC is involved in both homotypic and heterotypic
ALCAM-mediated adhesion
To investigate whether PKC involvement applies only to
homotypic ALCAM-ALCAM adhesion or also regulates
heterotypic adhesion of ALCAM to CD6 (the other
physiological ligand of ALCAM), we also examined the
interaction between ALCAM and immobilized CD6-Fc. In
contrast to ALCAM-ALCAM binding, we observed a
spontaneous interaction between ALCAM and CD6 that did
not require disruption of the actin cytoskeleton by CytD (Fig.
4D). However, adhesion was further increased after pre-
treatment with CytD. Inhibition of PKC by specific inhibitors
resulted in a markedly reduced ALCAM-CD6 binding, similar
to what we observed for the CytD-induced, homotypic
ALCAM-ALCAM interaction. These data point to an
important role of PKC in the regulation of both homotypic and
heterotypic adhesion mediated by ALCAM.
PKCa is the PKC isoform involved in ALCAM-mediated
adhesion
To further explore the involvement of PKC in ALCAM-
mediated adhesion, cells were cultured for 24 hours with PMA
(50 nM) to induce downregulation of PKC. Western blot
analysis revealed the expression of a number of PKC isotypes
in KG1 and K562-ALCAM cells (Table 1). We observed that
long-term PMA treatment dramatically lowered the amounts of
PKCa and PKCq (Fig. 5A), rendering homotypic ALCAM-
mediated adhesion unresponsive to CytD and LatA (Fig. 5B),
and reducing spontaneous K562-ALCAM adhesion to CD6-Fc
(not shown). Of note, this treatment did not affect the levels of
PKCz and PKCh (data not shown). Importantly, the overall
surface expression of ALCAM is not altered after long-term
Table 1. Expression of PKC isotypes in K562-ALCAM and
KG1 cells, as detected by western blot analysis
PKC isotype K562-ALCAM KG1 Control*
a ++ + ++
b – – +
g – – +
e – – ++
h +/– +/– +
z + + +
q + + ++
*Rabbit-brain homogenate.
–, no expression; +/–, weak expression; +, expression; ++, high expression.
Fig. 5. (A) Long-term PMA treatment leads to downregulation of
PKCa and PKC q . KG1 and K562-ALCAM cells were cultured for
24 hours in presence or absence of PMA (50 nM) to induce
downregulation of PKC. PKC expression was analyzed by western
blotting. PKC isotypes a and q are both downregulated upon
culturing in the presence of PMA in both cell lines. Expression of
PKC isotypes z and h was not affected (data not shown). (B) PMA
culturing inhibits cytoskeleton-dependent ALCAM-mediated
adhesion. KG1 cells were cultured for 16 hours in the presence
(white bars) or absence (black bars) of 50 nM PMA. Subsequently,
induction of adhesion by pre-incubation of the cells for 30 minutes at
37°C with CytD (2.5 m g/ml) or LatA (5 m g/ml) was determined, in
the presence or absence of the blocking antibody AZN-L50
(10 m g/ml). Downregulation of PKC upon culturing with PMA
inhibits CytD- and LatA-induced adhesion to background levels.
Similar observations were made for K562-ALCAM (not shown).
(C) PMA culturing does not affect the overall ALCAM expression.
ALCAM expression on KG1 cultured in the presence or absence of
PMA (50 nM) was determined by flow cytometry. Shaded
histograms represent isotype control staining and white histograms
represent ALCAM staining with mAb AZN-L50.
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exposure to PMA (Fig. 5C). These data demonstrate a
requirement for PKC in the regulation of ALCAM-mediated
adhesion. PKC a is the key player in this process, since the
inhibitor myristoylated PKC pseudosubstrate is specific for
PKCa and PKCb (but PKCb is not expressed), and because
strong downregulation of PKC a and PKCq was observed (Fig.
5A).
PKCa modulates the avidity rather than the affinity of
ALCAM
To investigate whether the block in CytD-induced ALCAM-
activation by inhibition or downregulation of PKC a reflects
changes in avidity or affinity of ALCAM, we performed a
soluble ALCAM-Fc-binding assay. Downregulation of PKC a
decreased the ligand-binding capacity of ALCAM expressed
by KG1 to a limited extent, while the affinity of K562-ALCAM
for ALCAM-Fc was not affected. Inhibition of PKC by
chelerythrine chloride or myristoylated PKC pseudosubstrate
did not significantly affect the affinity of either ALCAM-
expressing cells for ALCAM-Fc (Fig. 6A,B). These data
indicate that PKCa is involved in avidity- rather than affinity-
modulation of ALCAM.
Serine and threonine residues in the cytoplasmic
domain of ALCAM are not required for ALCAM-mediated
adhesion
We have previously demonstrated the importance of the
ALCAM cytoplasmic domain for cytoskeleton-dependent
adhesion using a GPI-linked mutant of ALCAM (Nelissen et
al., 2000b). To investigate whether the serine/threonine
residues in the cytoplasmic tail are direct PKC targets and
important in CytD-induced adhesion, we exchanged either the
serine or threonine residues of the cytoplasmic domain for
alanine residues. Both mutant ALCAM molecules were
transfected in K562 cells (yielding K562-ALCAM D Ser and
K562-ALCAM D Thr, respectively) and selected for expression
levels comparable with those of wild-type ALCAM (Fig. 7A).
Subsequently, the effect of the mutations on ALCAM-
mediated adhesion was analyzed. Neither substitution of the
serine-residues, nor of the threonine-residues had any effect on
spontaneous or CytD-induced ALCAM-mediated adhesion
(Fig. 7B).
We further investigated putative ALCAM phosphorylation
by immunoprecipitation of ALCAM from [32P]-phosphate
labeled K562-ALCAM and KG1 cells. No phosphorylated
ALCAM was detected in cells labeled with [32P]-phosphate,
not even after PKC stimulation with PMA (Fig. 7Cb). Long-
term PMA treatment resulted in an overall decrease of protein
phosphorylation due to downregulation of PKC activity.
Similar results were obtained with KG1 cells. As a control, the
presence of ALCAM in K562-ALCAM cells (but not in
parental K562 cells) was confirmed by immunoprecipitation
from [35S]-Met/Cys labeled cell lysates (Fig. 7Ca). In addition,
western blot analysis using phospho-serine- and phospho-
threonine-specific antibodies showed no serine- or
threonine-phosphorylation of wild-type ALCAM after
immunoprecipitation (data not shown). Together, our findings
demonstrate that the cytoplasmic tail is not a direct target of
PKC or other serine/threonine kinases, but that PKC probably
phosphorylates other (as yet unknown) molecules involved in
the control of ALCAM-mediated adhesion.
Discussion
Homotypic ALCAM-mediated adhesion is dynamically
regulated through the actin cytoskeleton. In the present study
we examined two signaling pathways potentially involved in
the regulation of ALCAM-mediated adhesion.
Since Rho-like GTPases are key players in regulating
cytoskeleton dynamics (Hall, 1998) and cellular adhesion
(D’Souza-Schorey et al., 1998; Gimond et al., 1999; Braga,
2002), we analyzed the involvement of RhoA, Rac1 and Cdc42
in ALCAM-mediated, cytoskeleton-dependent adhesion. We
observed activation of RhoA by CytD or LatA treatment in two
hematopoietic cell lines, in accordance with the findings of Ren
and co-workers (Ren et al., 1999), who demonstrated that CytD
treatment activated RhoA in fibroblasts. Interestingly, we
found that, in addition to RhoA, Rac1 and Cdc42 are activated
in response to CytD. The observed differences in GTPase
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Fig. 6. Effect of PKC downregulation or PKC inhibition on
ALCAM-affinity. Soluble ALCAM-Fc-binding assay with KG1 cells
(A) and K562-ALCAM (B) either cultured for 16 hours with (s) or
without (d) 50 nM PMA or pre-incubated for 10 minutes at 37°C
with chelerythrine chloride (5 m M, m) or myristoylated PKC
pseudosubstrate (100 m M, n). Cells are incubated with increasing
concentrations of soluble ALCAM-Fc and the percentage of cells
that have bound ligand is determined by flow cytometry. Data are
representative of three independent experiments.
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activation kinetics between K562 and KG1 cells may be due
to distinct sensitivity to actin cytoskeleton-disrupting agents,
or differences in the association of RhoGAPs and/or RhoGEFs.
No significant differences with respect to activation of Rho-
like GTPases were observed between ALCAM-expressing
cells plated on immobilized ALCAM-Fc or on BSA as a
control substrate. In fibroblasts, Rho activation is regulated by
a negative feedback loop dependent on cell-matrix adhesion,
resulting in downregulation of Rho in adherent cells, whereas
active Rho levels remain elevated in suspension cells (Ren et
al., 1999). Our data provide no evidence for the existence of
such a negative feedback loop induced by ALCAM-ALCAM-
mediated cell adhesion.
Expression of dominant negative or constitutively active
mutants of the Rho-like GTPases neither affected spontaneous
nor CytD-induced ALCAM-mediated adhesion. Furthermore,
constitutive activation of Rac1 caused by the introduction of
C1199-Tiam1, or treatment with the Rho-kinase inhibitor Y-
27632 had no effect on ALCAM-mediated adhesion. In
contrast, b 1-integrin-mediated adhesion and spreading on
fibronectin is enhanced by expression of constitutively active
Rac1 and Cdc42 in Jurkat cells (Del Pozo et al., 2003). We
conclude that, in sharp contrast to adhesion mediated by
integrins and cadherins, RhoA, Rac1 or Cdc42 are neither
activated in response to ALCAM activation, nor directly
required for induction of ALCAM-mediated adhesion.
Instead, PKC appears to be an important player in the
induction of cytoskeleton-dependent, homotypic ALCAM-
mediated adhesion. Based on the specificity of the PKC
inhibitors used, and on the pattern of downregulation of PKC
upon long-term PMA treatment, PKCa is the dominant isoform
driving adhesion by ALCAM. Although the involvement of
PKCq can never be completely ruled out, it is unlikely that
PKCq plays a significant role. PKCa has been shown to co-
localize with a range of cytoskeletal proteins including
intermediate filament proteins (vimentin), membrane-
cytoskeletal cross-linking proteins (MARCKS, ankyrin), and
components of the actin filaments (F-actin) and microtubules
(tubulin) (Keenan and Kelleher, 1998; Slater et al., 2000), and
is widely implicated in integrin-mediated adhesion (Altman and
Villalba, 2002; Li et al., 1998; McDowall et al., 2003).
All PKC isoforms have been shown to associate with F-actin
(Slater et al., 2000). The actin cytoskeleton and PKC probably
act in a coordinated manner, since disruption of the actin
cytoskeleton by CytD caused a dose-dependent increase in
expression and activation of PKC a in mesenchymal cells (Lim
et al., 2000). These findings may explain the requirement for
both disruption of the actin cytoskeleton and the presence of
active PKC a for homotypic ALCAM-mediated adhesion in
K562-ALCAM and KG1 cells. The crucial role for PKC a in
ALCAM-mediated adhesion is strengthened by the fact that
heterotypic ALCAM-CD6 adhesion requires active PKC a .
Both CytD and PMA treatment lead to an equivalent increase
in lateral mobility and adhesion of b 2-integrins (Kucik et al.,
1996; McDowall et al., 1998). However, for ALCAM-mediated
Fig. 7. (A) Surface expression of ALCAM on K562-ALCAM D Ser,
K562-ALCAM D Thr and wild-type K562-ALCAM. K562 cells were
transfected with expression constructs coding for mutant ALCAM
proteins and were sorted to obtain homogeneous cell populations
expressing similar levels of mutant ALCAM. Expression was
analyzed by flow cytometry. The shaded histograms represent isotype
control staining and the white histograms represent staining with
ALCAM-antibody AZN-L50. (B) Replacement of serine- or
threonine residues in the cytoplasmic domain of ALCAM does not
affect spontaneous or CytD-induced adhesion. Adhesion of K562-
ALCAMD Ser, K562-ALCAM D Thr and K562-ALCAM was
analyzed after treatment of cells with or without CytD (2.5 m g/ml) as
in Fig. 1B. Wild-type and mutant ALCAM-expressing cells show
similar patterns of adhesion. Data are representative of three
experiments. (C) No evidence for phosphorylation of ALCAM after
treatment with [32P]-phosphate. K562 and K562-ALCAM cells were
incubated overnight with [35S]methionine/cysteine (a) or for 3 hours
with [32P]-disodiumphosphate (b). Cells were pre-incubated with
50 nM PMA for 16 hours prior to [32P]-phosphate labeling (PKC
downregulation), or 15 minutes after [32P]-phosphate labeling (PKC
activation), respectively. ALCAM was immunoprecipitated from
labeled cell lysates with 1 m g of AZN-L51. ALCAM was detected in
[35S]methionine/cysteine labeled K562-ALCAM lysate, but no
[32P]phosphate-labeled ALCAM could be detected, not even after
PMA stimulation. Long-term PMA treatment resulted in decreased
overall protein phosphorylation. Similar observations were made
with KG1 cells (not shown).
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adhesion, stimulation with phorbol ester alone is not sufficient
to induce adhesion.
The macrophage-enriched, myristoylated, alanine-rich C
kinase substrate (MacMARCKS), a direct PKC substrate, was
shown to be required for releasing the cytoskeletal restraints
on integrin molecules during PKC-mediated integrin activation
(Zhou and Li, 2000). However, we observed that PKC
activation (and hence the subsequent phosphorylation of
MARCKS) by short-term treatment with PMA neither induced
spontaneous adhesion nor altered CytD-induced adhesion.
Thus, although we cannot rule out a function for MARCKS in
ALCAM-mediated adhesion, MARCKS activation alone is not
sufficient for the induction of adhesion.
The cytoplasmic domain of ALCAM is not a direct target
for PKC, since it was not phosphorylated, not even after PKC
activation (Fig. 7C). Although two serines and two threonines
are present in the cytoplasmic domain of ALCAM, the
cytoplasmic domain does not contain conserved PKC-
phosphorylation motifs. Moreover, mutation of either the
serine or threonine residues did not affect cytoskeleton-
dependent adhesion. Therefore, induction of ALCAM-
mediated adhesion in response to CytD and PKC probably
depends on other cytoskeletal components subject to PKC-
regulation.
An important group of proteins that constitute a link between
extracellular receptors and the intracellular cytoskeleton is the
ezrin/radixin/moesin (ERM) family. These proteins bind actin
filaments through their C-terminal domain and the conserved
globular N-terminal half associates with the cytoplasmic
domains of several other transmembrane adhesion receptors
such as CD43 (Serrador et al., 1998), CD44 (Legg and Isacke,
1998), ICAM-1, ICAM-2 (Heiska et al., 1998), ICAM-3
(Serrador et al., 1997) and L1-CAM (Dickson et al., 2002).
ERM proteins, in cooperation with Rho-like GTPases, are
involved in the formation of stress fibers and focal adhesions
(Mackay and Hall, 1998) and in the clustering of adhesion
receptors (Wojciak-Stothard et al., 1999). They bind positively
charged amino acid clusters in the cytoplasmic domains of
CD44, CD43 and ICAM-2 (Yonemura et al., 1998), which
makes this family of proteins candidates to bind to the highly
charged cytoplasmic domain of ALCAM as well. However,
thus far we have not been successful in confirming this
association by GST pulldown assays or immunoprecipitations
(our unpublished results), again demonstrating that ALCAM-
mediated adhesion is differently regulated compared with other
adhesion molecules.
Two actin bundling proteins, fascin and filamin, are
substrates for PKC a and are candidates in the cytoskeleton-
dependent regulation of ALCAM-mediated adhesion. Filamin
promotes actin filament branching and stabilizes microfilament
networks (Gorlin et al., 1990). Some b -integrin tails bind
tightly to filamin, thereby restricting integrin-dependent cell
migration by inhibiting transient membrane protrusion and cell
polarization (Calderwood et al., 2001). Fascin is localized
mainly at filopodia and membrane ruffles, as well as in stress
fibres (Yamashiro-Matsumura and Matsumura, 1986). The
actin bundling activity of fascin modulates the actin
cytoskeleton, and is regulated by phosphorylation by PKC a
(Adams et al., 1999).
Tomita and co-workers reported that ALCAM is co-
recruited to sites of cell-cell contact upon correct assembly of
E-cadherin/ a -catenin complexes in epithelial cells (Tomita et
al., 2000). Catenins link cadherins and, for example, PECAM-
1 to the actin cytoskeleton (Ilan et al., 1999). Moreover,
catenins can be phosphorylated by PKC and association of
g -catenin to PECAM-1 depends on phosphorylation (Ilan et
al., 2000). Thus, catenins constitute a link between various
adhesion molecules and PKC-signaling pathways. These
findings suggest that a -catenin is another potential candidate
linking the ALCAM-cytoplasmic domain to the actin
cytoskeleton.
Although the PKC-substrate responsible for mediating
ALCAM-mediated adhesion remains to be identified, we show
here that the release of ALCAM from cytoskeletal restraints is
essential for the induction of adhesion and requires PKC a .
This PKC involvement is restricted to avidity modulation,
since ligand-binding affinity is not changed by activation or
inhibition of PKC. However, PKC a is not directly involved in
ALCAM cluster formation, since PKC inhibition does not
affect the cell surface distribution of ALCAM. Interestingly,
regulation of ALCAM by the cytoskeleton differs from other
adhesion molecules, such as integrins, cadherins and other Ig-
like cell adhesion molecules, in that small Rho-like GTPases
do not appear to be directly involved. Future research will
unravel the physiological stimuli that generate ‘inside-out’
signals that induce cytoskeleton- and PKC-dependent
ALCAM-mediated adhesion, either through avidity or affinity
modulation.
We thank R. Torensma for providing the AZN-L50 and AZN-L51
antibodies. The Microscopic Imaging Center (MIC) of the NCMLS is
kindly acknowledged for its technical support.
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